A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.
Multiple Myeloma and Malignant Lymphoma
DRUG: KRN125(pegfilgrastim), PLR001(plerixafor)|DRUG: KRN8601(filgrastim), PLR001(plerixafor)
Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma., Day 5, 6, 7
Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with malignant lymphoma., Day 1, 4, 5, 6, 7
Number of participants with treatment-emergent adverse events (TEAEs), Day 30 or initiation of radiotherapy or chemotherapy|Serum KRN125 concentrations, Day 30 or initiation of radiotherapy or chemotherapy|Anti-KRN125 antibody, Day 30 or initiation of radiotherapy or chemotherapy
To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.